COMPASS Pathways
Business Services · United Kingdom · 51-200 Employees
View Company Info for Free
Overview
Headquarters
33 Broadwick St, London, Greater London,...Phone Number
+44 7166766461Website
www.compasspathways.comRevenue
$132 MillionStock Symbol
CMPSIndustry
ZI Rank: 2
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
3
4
1
2
2
About COMPASS Pathways
COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support.Explore more
COMPASS Pathways Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is COMPASS Pathways your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if COMPASS Pathways is spiking on competitors!
COMPASS Pathways, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when COMPASS Pathways launches new products
Earning: See what the market has to say on COMPASS Pathways recently announced quarterly report
Click to see if COMPASS Pathways had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once COMPASS Pathways has new funding data
Check if COMPASS Pathways has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at COMPASS Pathways
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined COMPASS Pathways as Masked Content
Find 2 more new buyers
Compare Similar Companies to COMPASS Pathways
Compare insights from companies similar to COMPASS Pathways, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
COMPASS Pathways is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
COMPASS Pathways is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about COMPASS Pathways.
COMPASS Pathways financials insights
Gather financial insights about COMPASS Pathways, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$35.5M
2020
Series B
$80M
Stock Offering
$128M
2023
Debt
$50M
Other Financing Round
$285M
COMPASS Pathways Tech Stack
A closer look at the technologies used by COMPASS Pathways
See more technologies
Most Recent Scoops
Project
expects the label for COMP360 to cover the treatment of treatment-resistant depression broadly, without restriction to adjunctive or monotherapy use, based on data being collected in Part C of its clinical trials.
Medical Research, Clinical Operations
Project
began launch readiness preparations following early FDA discussions about a rolling submission and potential accelerated review, incorporating analysis of a truncated review timeline and shortened DEA scheduling scenarios to ensure readiness by year-end.
Pharmaceuticals, Clinical Operations, Regulations
Project
anticipates that the label for COMP360 will reflect one or two initial treatments with episodic retreatment, with a reasonable expectation of two to four treatments per year, based on data from studies 005 and 006 including open-label Phase C data.
Pharmaceuticals
Project
COMPASS Pathways has been issued a National Priority Voucher following a presidential executive order, committing the FDA to a target approval timeline of 60 days from the date of submission for COMP360.
Project
Pharmaceuticals
COMPASS Pathways News & Media
Compass Pathways Eyes 2027 Launch as Psilocybin Depression Data Holds Up
Compass Pathways (NASDAQ:CMPS) said new 26-week data from its Phase 3 COMP006 trial further support the durability and safety profile of COMP360, its investigational psilocybin therapy for treatment-resistant depression, as the company works toward a potential U.S. launch in the first half of 2027.COMPASS Pathways plc (CMPS) Discusses Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile in Depression Transcript
COMPASS Pathways plc (CMPS) Discusses Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile in Depression July 7, 2026 8:00 AM...Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing ...
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to eight newly hired non-executive employees. The equity awards were granted on July 1, 2026 and consisted of options to purchase an aggregate of 63,685 shares and restricted share units or, in the case of employees in the United Kingdom nominalIs COMPASS Pathways plc (CMPS) A Good Stock To Buy Now?
Is CMPS a good stock to buy? We came across a bullish thesis on COMPASS Pathways plc on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on CMPS. COMPASS Pathways plc’s share was trading at $11.26 as of June 9th. COMPASS Pathways plc operates as a biotechnology company that focuses on mental health […]
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding COMPASS Pathways
Sign Up For FreeTo access detailed company insights
COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psi... Read More
